נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo
Year:
2003
Source of publication :
Clinical Cancer Research
Authors :
Pines, Mark
;
.
Volume :
9
Co-Authors:
Gross, D.J., Endocrinology and Metabolism Service, Hadassah University Hospital, Jerusalem 91120, Israel, Inst. of Endocrinol. and Metabolism, Rabin Medical Center, Beilinson Campus, Petach-Tikva 49100, Israel
Reibstein, I., Dept. of Bone Marrow Transplant., Hadassah University Hospital, Jerusalem 91120, Israel
Weiss, L., Dept. of Bone Marrow Transplant., Hadassah University Hospital, Jerusalem 91120, Israel
Slavin, S., Dept. of Bone Marrow Transplant., Hadassah University Hospital, Jerusalem 91120, Israel
Dafni, H., Department of Biological Regulation, Weitzmann Institute of Science, Rehovot 76100, Israel
Neeman, M., Department of Biological Regulation, Weitzmann Institute of Science, Rehovot 76100, Israel
Pines, M., Institute of Animal Science, Volcani Center, Bet Dagan, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Sheba Medical Center, Tel-Hashomer, Israel
Facilitators :
From page:
3788
To page:
3793
(
Total pages:
6
)
Abstract:
Halofuginone has recently been shown to inhibit tumor progression of various types of cancers. The antitumoral effect was associated with decreased tumor angiogenesis rather than a direct cytostatic effect on the tumor cells. The antiangiogenic action of the drug could be related to its inhibition of collagen type I synthesis, inhibition of matrix metalloproteinases (MMPs), or via both mechanisms because both collagen synthesis and MMP activity have been shown to be involved in angiogenesis. Vascular endothelial growth factor (VEGF), in addition to its effect on endothelial cell proliferation, has been shown to be a potent inducer of MMP expression. Because von Hippel-Lindau (VHL)-associated tumors express high levels of VEGF, it was of interest to ascertain the potential usefulness of halofuginone for treatment of these tumors. Pheochromocytoma tissue fragments obtained at surgery from a VHL type 2a patient were propagated s.c. in male BALB/c v/v (nude) mice. For experiments, 2-3-mm tumor fragments were transplanted secondarily s.c. to nude mice. Two treatment groups received halofuginone in standard lab chow at 3 and 5 ppm; control animals received regular chow. All groups were followed for 6 weeks after transplantation. A marked and significant diminution of tumor size and weight was observed in the drug-treated animals (>90% reduction of mean tumor volume for both the 3 and 5 ppm groups). In vivo magnetic resonance imaging analysis of tumors in halofuginone-treated animals showed a significant reduction of vascular functionality. Immunohistoehemical studies revealed decreased collagen type I levels and vascular density in treated tumors and gelatinase assays of tumor extracts revealed a reduction of MMP-2 and MMP-9 activity in halofuginone-treated cells. Taken together, our data indicate that therapy directed at blocking MMP activity (presumably related to excessive VEGF expression in VHL) and reduction of type I collagen deposition curtails angiogenesis and thereby presumably tumor growth in this model system.
Note:
Related Files :
Animals
Magnetic Resonance Imaging
Male
mice
nude mouse
temperature
Tumor Suppressor Proteins
Show More
Related Content
More details
DOI :
Article number:
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
29662
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 00:48
You may also be interested in
Scientific Publication
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo
9
Gross, D.J., Endocrinology and Metabolism Service, Hadassah University Hospital, Jerusalem 91120, Israel, Inst. of Endocrinol. and Metabolism, Rabin Medical Center, Beilinson Campus, Petach-Tikva 49100, Israel
Reibstein, I., Dept. of Bone Marrow Transplant., Hadassah University Hospital, Jerusalem 91120, Israel
Weiss, L., Dept. of Bone Marrow Transplant., Hadassah University Hospital, Jerusalem 91120, Israel
Slavin, S., Dept. of Bone Marrow Transplant., Hadassah University Hospital, Jerusalem 91120, Israel
Dafni, H., Department of Biological Regulation, Weitzmann Institute of Science, Rehovot 76100, Israel
Neeman, M., Department of Biological Regulation, Weitzmann Institute of Science, Rehovot 76100, Israel
Pines, M., Institute of Animal Science, Volcani Center, Bet Dagan, Israel
Nagler, A., Dept. of Bone Marrow Transplantation, Sheba Medical Center, Tel-Hashomer, Israel
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo
Halofuginone has recently been shown to inhibit tumor progression of various types of cancers. The antitumoral effect was associated with decreased tumor angiogenesis rather than a direct cytostatic effect on the tumor cells. The antiangiogenic action of the drug could be related to its inhibition of collagen type I synthesis, inhibition of matrix metalloproteinases (MMPs), or via both mechanisms because both collagen synthesis and MMP activity have been shown to be involved in angiogenesis. Vascular endothelial growth factor (VEGF), in addition to its effect on endothelial cell proliferation, has been shown to be a potent inducer of MMP expression. Because von Hippel-Lindau (VHL)-associated tumors express high levels of VEGF, it was of interest to ascertain the potential usefulness of halofuginone for treatment of these tumors. Pheochromocytoma tissue fragments obtained at surgery from a VHL type 2a patient were propagated s.c. in male BALB/c v/v (nude) mice. For experiments, 2-3-mm tumor fragments were transplanted secondarily s.c. to nude mice. Two treatment groups received halofuginone in standard lab chow at 3 and 5 ppm; control animals received regular chow. All groups were followed for 6 weeks after transplantation. A marked and significant diminution of tumor size and weight was observed in the drug-treated animals (>90% reduction of mean tumor volume for both the 3 and 5 ppm groups). In vivo magnetic resonance imaging analysis of tumors in halofuginone-treated animals showed a significant reduction of vascular functionality. Immunohistoehemical studies revealed decreased collagen type I levels and vascular density in treated tumors and gelatinase assays of tumor extracts revealed a reduction of MMP-2 and MMP-9 activity in halofuginone-treated cells. Taken together, our data indicate that therapy directed at blocking MMP activity (presumably related to excessive VEGF expression in VHL) and reduction of type I collagen deposition curtails angiogenesis and thereby presumably tumor growth in this model system.
Scientific Publication
You may also be interested in